PFE · Pfizer Inc.

0000078003-26-000054

SEC filing

Summary

Revenue was $14.5B (5.4%) Gross Profit was $10.9B (30.4%) Net Income was $2.7B (-9.4%) Eps was $0.47 (-9.6%)

Key takeaways

Revenue was $14.5B, up 5.4% year-over-year, reflecting continued global demand across key products.
Net income was $2.7B, down 9.4% year-over-year, and diluted EPS was $0.47, down 9.6%, due to a higher effective tax rate.
The increase in the effective tax rate for Q1 2026, compared to Q1 2025, was primarily due to an unfavorable change in the jurisdictional mix of earnings and non-recurrence of favorable global income tax resolutions.

Full analysis

Effective Tax Rate

The effective tax rate increased in Q1 2026 compared to Q1 2025, primarily due to an unfavorable change in the jurisdictional mix of earnings and the non-recurrence of favorable global income tax resolutions from the prior year. This dynamic directly contributed to the year-over-year decline in net income and diluted EPS, despite top-line growth and stable gross margin performance.

PFE · Pfizer Inc.

Summary

Key takeaways

Full analysis

Effective Tax Rate

Revenue and Gross Profit

Cash Flow and Capital Allocation

Financial Position and Outlook